{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:44:10Z","timestamp":1784133850109,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1D1A1B03033499"],"award-info":[{"award-number":["2017R1D1A1B03033499"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015R1D1A1A01057508"],"award-info":[{"award-number":["2015R1D1A1A01057508"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015R1D1A1A01057508"],"award-info":[{"award-number":["2015R1D1A1A01057508"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1D1A1B03033499"],"award-info":[{"award-number":["2017R1D1A1B03033499"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016R1A2B4015866"],"award-info":[{"award-number":["2016R1A2B4015866"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2015R1D1A1A01057508"],"award-info":[{"award-number":["2015R1D1A1A01057508"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1D1A1B03033499"],"award-info":[{"award-number":["2017R1D1A1B03033499"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuroblastoma is a solid malignant tumor of the sympathetic nervous system, which accounts for 8\u201310% of childhood cancers. Considering the overall high risk and poor prognosis associated with neuroblastoma, effective therapeutics should be developed to improve patient survival and quality of life. A recent study showed that a proteasome inhibitor, carfilzomib (CFZ), reduced cell viability of SK-N-BE(2)-M17 neuroblastoma cells. Therefore, we investigated the molecular mechanisms by which CFZ lower the cell viability of neuroblastoma cells. CFZ reduced cell viability via cell cycle arrest at G2\/M and apoptosis, which involved caspase activation (caspases-8, 9, 4, and 3), endoplasmic reticulum stress, reactive oxygen species production, mitochondrial membrane potential loss, and autophagy in a dose- and time-dependent manner. The effect of CFZ was additive to that of cisplatin (Cis), a well-known chemotherapeutic drug, in terms of cell viability reduction, cell cycle arrest, and apoptosis. Importantly, the additive effect of CFZ was maintained in Cis-resistant neuroblastoma cells. These results suggest that CFZ can be used in combination therapy for patients with neuroblastoma to overcome the resistance and adverse side effects of Cis.<\/jats:p>","DOI":"10.1038\/s41598-019-41527-0","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T11:03:11Z","timestamp":1553511791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells"],"prefix":"10.1038","volume":"9","author":[{"given":"Song-I","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Ju","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah-Ran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeok Jin","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insug","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Ju","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"issue":"24","key":"41527_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12929-017-0319-y","volume":"16","author":"MR Esposito","year":"2017","unstructured":"Esposito, M. R., Aveic, S., Seydel, A. & Tonini, G. P. Neuroblastoma treatment in the post-genomic era. Biomedical Science 16(24), 14 (2017).","journal-title":"Biomedical Science"},{"key":"41527_CR2","doi-asserted-by":"crossref","unstructured":"Yalcin, B., Kremer, L. C. & van Dalen, E. C. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst. Rev., CD006301 (2015).","DOI":"10.1002\/14651858.CD006301.pub4"},{"key":"41527_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/sj.eye.6701912","volume":"20","author":"S Ahmed","year":"2006","unstructured":"Ahmed, S. et al. Neuroblastoma with orbital metastasis: ophthalmic presentation and role of ophthalmologists. Eye (Lond) 20, 466\u2013470 (2006).","journal-title":"Eye (Lond)"},{"key":"41527_CR4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jama.2012.228","volume":"307","author":"NK Cheung","year":"2012","unstructured":"Cheung, N. K. et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307, 1062\u20131071 (2012).","journal-title":"JAMA"},{"key":"41527_CR5","doi-asserted-by":"crossref","first-page":"75914","DOI":"10.18632\/oncotarget.12427","volume":"7","author":"S Guan","year":"2016","unstructured":"Guan, S. et al. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis. Oncotarget 7, 75914\u201375925 (2016).","journal-title":"Oncotarget"},{"key":"41527_CR6","first-page":"CD010685","volume":"8","author":"F Peinemann","year":"2017","unstructured":"Peinemann, F., van Dalen, E. C., Enk, H. & Berthold, F. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst. Rev. 8, CD010685 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"41527_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","volume":"18","author":"R Ladenstein","year":"2017","unstructured":"Ladenstein, R. et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. The Lancet Oncology 18, 500\u2013514 (2017).","journal-title":"The Lancet Oncology"},{"key":"41527_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","volume":"121","author":"KM Kortuem","year":"2013","unstructured":"Kortuem, K. M. & Stewart, A. K. Carfilzomib. Blood 121, 893\u2013897 (2013).","journal-title":"Blood"},{"key":"41527_CR9","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","volume":"114","author":"F Parlati","year":"2009","unstructured":"Parlati, F. et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114, 3439\u20133447 (2009).","journal-title":"Blood"},{"key":"41527_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-5-18","volume":"5","author":"M Boccadoro","year":"2005","unstructured":"Boccadoro, M., Morgan, G. & Cavenagh, J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5, 18 (2005).","journal-title":"Cancer Cell Int."},{"key":"41527_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-014-0111-8","volume":"33","author":"AF Baker","year":"2014","unstructured":"Baker, A. F. et al. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models. J. Exp. Clin. Cancer Res. 33, 111 (2014).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"41527_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjh.13900","volume":"172","author":"T Watanabe","year":"2016","unstructured":"Watanabe, T. et al. A phase 1\/2 study of carfilzomib in Japanese patients with relapsed and\/or refractory multiple myeloma. Br. J. Haematol. 172, 745\u2013756 (2016).","journal-title":"Br. J. Haematol."},{"key":"41527_CR13","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1158\/1535-7163.MCT-13-0156","volume":"12","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Molecular cancer therapeutics 12, 2494\u20132504 (2013).","journal-title":"Molecular cancer therapeutics"},{"key":"41527_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00280-017-3489-0","volume":"81","author":"MSF Roeten","year":"2018","unstructured":"Roeten, M. S. F., Cloos, J. & Jansen, G. Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer chemotherapy and pharmacology 81, 227\u2013243 (2018).","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"41527_CR15","doi-asserted-by":"publisher","first-page":"8608","DOI":"10.1038\/sj.onc.1207108","volume":"22","author":"DG Breckenridge","year":"2003","unstructured":"Breckenridge, D. G., Germain, M., Mathai, J. P., Nguyen, M. & Shore, G. C. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22, 8608\u20138618 (2003).","journal-title":"Oncogene"},{"key":"41527_CR16","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1002\/bit.23282","volume":"108","author":"A Chakrabarti","year":"2011","unstructured":"Chakrabarti, A., Chen, A. W. & Varner, J. D. A review of the mammalian unfolded protein response. Biotechnology and bioengineering 108, 2777\u20132793 (2011).","journal-title":"Biotechnology and bioengineering"},{"key":"41527_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1097-2765(00)00108-8","volume":"6","author":"HP Harding","year":"2000","unstructured":"Harding, H. P. et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell. 6, 1099\u20131108 (2000).","journal-title":"Mol. Cell."},{"key":"41527_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/ncb0311-184","volume":"13","author":"I Tabas","year":"2011","unstructured":"Tabas, I. & Ron, D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nature cell biology 13, 184\u2013190 (2011).","journal-title":"Nature cell biology"},{"key":"41527_CR19","doi-asserted-by":"publisher","first-page":"11269","DOI":"10.1073\/pnas.0400541101","volume":"101","author":"KM Vattem","year":"2004","unstructured":"Vattem, K. M. & Wek, R. C. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 101, 11269\u201311274 (2004).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"41527_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1177\/1087057111414893","volume":"16","author":"AM Fribley","year":"2011","unstructured":"Fribley, A. M. et al. Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response. Journal of biomolecular screening 16, 825\u2013835 (2011).","journal-title":"Journal of biomolecular screening"},{"key":"41527_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm3270","volume":"13","author":"C Hetz","year":"2012","unstructured":"Hetz, C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nature reviews. Molecular cell biology 13, 89\u2013102 (2012).","journal-title":"Nature reviews. Molecular cell biology"},{"key":"41527_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/1673-5374.198970","volume":"12","author":"PG Sreekumar","year":"2017","unstructured":"Sreekumar, P. G., Hinton, D. R. & Kannan, R. Endoplasmic reticulum-mitochondrial crosstalk: a novel role for the mitochondrial peptide humanin. Neural regeneration research 12, 35\u201338 (2017).","journal-title":"Neural regeneration research"},{"key":"41527_CR23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s10495-012-0755-9","volume":"17","author":"JH Choi","year":"2012","unstructured":"Choi, J. H. et al. Apicidin induces endoplasmic reticulum stress- and mitochondrial dysfunction-associated apoptosis via phospholipase Cgamma1- and Ca(2+)-dependent pathway in mouse Neuro-2a neuroblastoma cells. Apoptosis 17, 1340\u20131358 (2012).","journal-title":"Apoptosis"},{"key":"41527_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejphar.2011.06.047","volume":"668","author":"AY Choi","year":"2011","unstructured":"Choi, A. Y. et al. Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells. Eur. J. Pharmacol. 668, 115\u2013126 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"41527_CR25","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1016\/j.bbamcr.2013.06.028","volume":"1833","author":"R Sano","year":"2013","unstructured":"Sano, R. & Reed, J. C. ER stress-induced cell death mechanisms. Biochim. Biophys. Acta 1833, 3460\u20133470 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"41527_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/157489206775246539","volume":"1","author":"S Fulda","year":"2006","unstructured":"Fulda, S. & Debatin, K. M. Targeting inhibitor of apoptosis proteins (IAPs) for diagnosis and treatment of human diseases. Recent patents on anti-cancer drug discovery 1, 81\u201389 (2006).","journal-title":"Recent patents on anti-cancer drug discovery"},{"key":"41527_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cytogfr.2008.04.001","volume":"19","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi, A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19, 325\u2013331 (2008).","journal-title":"Cytokine Growth Factor Rev"},{"key":"41527_CR28","first-page":"3","volume":"1","author":"Z Hongmei","year":"2012","unstructured":"Hongmei, Z. Extrinsic and Intrinsic Apoptosis Signal Pathway Review. Apoptosis and Medicine 1, 3\u201322 (2012).","journal-title":"Apoptosis and Medicine"},{"key":"41527_CR29","doi-asserted-by":"publisher","first-page":"a008656","DOI":"10.1101\/cshperspect.a008656","volume":"5","author":"DR McIlwain","year":"2013","unstructured":"McIlwain, D. R., Berger, T. & Mak, T. W. Caspase functions in cell death and disease. Cold Spring Harbor perspectives in biology 5, a008656 (2013).","journal-title":"Cold Spring Harbor perspectives in biology"},{"key":"41527_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari, S. & Tchounwou, P. B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740, 364\u2013378 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"41527_CR31","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/jps.20874","volume":"96","author":"T Ozben","year":"2007","unstructured":"Ozben, T. Oxidative stress and apoptosis: impact on cancer therapy. Journal of pharmaceutical sciences 96, 2181\u20132196 (2007).","journal-title":"Journal of pharmaceutical sciences"},{"key":"41527_CR32","first-page":"1","volume":"2010","author":"A Basu","year":"2010","unstructured":"Basu, A. & Krishnamurthy, S. Cellular responses to Cisplatin-induced DNA damage. Journal of nucleic acids 2010, 1\u201316 (2010).","journal-title":"Journal of nucleic acids"},{"key":"41527_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"AM Florea","year":"2011","unstructured":"Florea, A. M. & Busselberg, D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3, 1351\u20131371 (2011).","journal-title":"Cancers (Basel)"},{"key":"41527_CR34","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869\u20131883 (2012).","journal-title":"Oncogene"},{"key":"41527_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.cdd.4400476","volume":"6","author":"AG Porter","year":"1999","unstructured":"Porter, A. G. & Janicke, R. U. Emerging roles of caspase-3 in apoptosis. Cell death and differentiation 6, 99\u2013104 (1999).","journal-title":"Cell death and differentiation"},{"key":"41527_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mrfmmm.2004.06.056","volume":"569","author":"M Schroder","year":"2005","unstructured":"Schroder, M. & Kaufman, R. J. ER stress and the unfolded protein response. Mutat. Res. 569, 29\u201363 (2005).","journal-title":"Mutat. Res."},{"key":"41527_CR37","doi-asserted-by":"publisher","first-page":"e76662","DOI":"10.1371\/journal.pone.0076662","volume":"8","author":"G Wang","year":"2013","unstructured":"Wang, G. et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One 8, e76662 (2013).","journal-title":"PLoS One"},{"key":"41527_CR38","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MOP.0b013e32832b1240","volume":"21","author":"KA Bowen","year":"2009","unstructured":"Bowen, K. A. & Chung, D. H. Recent advances in neuroblastoma. Curr. Opin. Pediatr. 21, 350\u2013356 (2009).","journal-title":"Curr. Opin. Pediatr."},{"key":"41527_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-med-011514-023121","volume":"66","author":"CU Louis","year":"2015","unstructured":"Louis, C. U. & Shohet, J. M. Neuroblastoma: molecular pathogenesis and therapy. Annu. Rev. Med. 66, 49\u201363 (2015).","journal-title":"Annu. Rev. Med."},{"key":"41527_CR40","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris, J. M. Recent advances in neuroblastoma. The New England journal of medicine 362, 2202\u20132211 (2010).","journal-title":"The New England journal of medicine"},{"key":"41527_CR41","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3892\/ijo.2014.2513","volume":"45","author":"W Tang","year":"2014","unstructured":"Tang, W. et al. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-kappaB in vitro and in vivo. Int. J. Oncol. 45, 995\u20131010 (2014).","journal-title":"Int. J. Oncol."},{"key":"41527_CR42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1530\/ERC-14-0510","volume":"22","author":"A Mehta","year":"2015","unstructured":"Mehta, A. et al. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer. Endocrine-related cancer 22, 319\u2013329 (2015).","journal-title":"Endocrine-related cancer"},{"key":"41527_CR43","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/abbs\/gmu030","volume":"46","author":"M Gao","year":"2014","unstructured":"Gao, M. et al. Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells. Acta biochimica et biophysica Sinica 46, 484\u2013491 (2014).","journal-title":"Acta biochimica et biophysica Sinica"},{"key":"41527_CR44","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.tjog.2016.09.003","volume":"55","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y., Wang, K., Zhen, S., Wang, R. & Luo, W. Carfilzomib induces G2\/M cell cycle arrest in human endometrial cancer cells via upregulation of p21(Waf1\/Cip1) and p27(Kip1). Taiwanese journal of obstetrics & gynecology 55, 847\u2013851 (2016).","journal-title":"Taiwanese journal of obstetrics & gynecology"},{"key":"41527_CR45","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-15-2522","volume":"22","author":"B Lamothe","year":"2016","unstructured":"Lamothe, B., Wierda, W. G., Keating, M. J. & Gandhi, V. Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clinical cancer research: an official journal of the American Association for Cancer Research 22, 4712\u20134726 (2016).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"41527_CR46","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-12-1213","volume":"18","author":"Y Zang","year":"2012","unstructured":"Zang, Y. et al. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clinical cancer research: an official journal of the American Association for Cancer Research 18, 5639\u20135649 (2012).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"41527_CR47","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.4161\/auto.22185","volume":"8","author":"Y Zang","year":"2012","unstructured":"Zang, Y. et al. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy 8, 1873\u20131874 (2012).","journal-title":"Autophagy"},{"key":"41527_CR48","first-page":"3668","volume":"38","author":"Y Jiang","year":"2017","unstructured":"Jiang, Y. et al. Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein. Oncology reports 38, 3668\u20133676 (2017).","journal-title":"Oncology reports"},{"key":"41527_CR49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/leu.2015.190","volume":"30","author":"EE Fink","year":"2016","unstructured":"Fink, E. E. et al. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells. Leukemia 30, 104\u2013111 (2016).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41527-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41527-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41527-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:08:44Z","timestamp":1671264524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41527-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41527"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41527-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5039"}}